SweetValueLab
Write for us

Edwards Lifesciences Corporation — Wall Street Analyst Estimates & Price Targets

EW
NYSEHealthcareMedical - DevicesCIK 0001099800edwards.comAbout EW
Last close · Oct 16, 202686.60−1.50 (−1.70%)
Market cap$49.9B

3 firms' latest targets, last 90 days: median $101.00 ($101.00–$110.00), 17% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$70.0$80.0$90.0$100$110NovJan 2026MarMayJulSep2025-10-27 · Truist: $82.02025-10-28 · Truist: $87.02025-10-29 · Jefferies: $98.02025-10-31 · National Bank: $92.02025-10-31 · Goldman Sachs: $1042025-10-31 · RBC Capital: $95.02025-10-31 · Baird: $83.02025-10-31 · Barclays: $99.02025-11-03 · Bernstein: $90.02025-11-03 · UBS: $90.02025-11-03 · Canaccord Genuity: $84.02025-11-03 · Raymond James: $96.02025-12-04 · BTIG: $1032025-12-05 · UBS: $92.02025-12-05 · RBC Capital: $1002025-12-05 · Baird: $88.02025-12-05 · Canaccord Genuity: $89.02025-12-05 · Wells Fargo: $96.02025-12-05 · Stifel: $1002025-12-05 · Truist: $92.02025-12-08 · Barclays: $1032025-12-16 · Baird: $87.02025-12-17 · Canaccord Genuity: $87.02025-12-18 · Wells Fargo: $1002026-01-05 · Evercore ISI: $94.02026-01-07 · Stifel: $1052026-01-09 · Goldman Sachs: $1082026-01-12 · UBS: $95.02026-01-12 · Baird: $90.02026-01-12 · Barclays: $1042026-01-20 · Stifel: $1102026-01-20 · Piper Sandler: $98.02026-02-04 · UBS: $94.02026-02-11 · Truist: $89.02026-02-11 · Goldman Sachs: $95.02026-02-11 · Piper Sandler: $1002026-04-13 · Mizuho Securities: $95.02026-04-24 · Truist: $90.02026-04-24 · Evercore ISI: $93.02026-04-24 · BTIG: $1002026-04-24 · Canaccord Genuity: $85.02026-04-27 · Barclays: $1102026-06-30 · BTIG: $1102026-07-06 · Evercore ISI: $1002026-07-13 · RBC Capital: $1102026-07-16 · Truist: $95.02026-07-24 · Piper Sandler: $1012026-07-24 · Leerink Partners: $1012026-07-28 · UBS: $110
$70.0$80.0$90.0$100$110NovFebMayAug

Each firm's latest target

last 90 days · 3 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-07-28UBS$110.00$94.00▲ 17%+32%+27%
2026-07-24Piper Sandler$101.00$100.00▲ 1%+20%+17%
2026-07-24Leerink Partners$101.00——+20%+17%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$6.0B+12%$2.30-6%est. $6.0B+1%est. $2.5120
2024reported$5.4B-9%$6.97+203%est. $5.8B-6%est. $2.5716
2025reported$6.1B+12%$1.83-74%est. $6.0B+0%est. $2.6022
2026$6.8B+12%$3.00+16%$6.7B–$6.8B$2.97–$3.0521
2027$7.4B+10%$3.39+13%$7.2B–$7.5B$3.29–$3.4621
2028$8.2B+11%$3.81+12%$7.9B–$8.6B$3.66–$3.8920
2029$9.0B+10%$4.20+10%$8.8B–$9.2B$4.07–$4.3210
2030$9.8B+9%$4.62+10%$9.6B–$10.0B$4.47–$4.7610
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.